TY - JOUR
T1 - Interlaboratory comparison of endotoxin contamination assessment of nanomaterials
AU - Hannon, Gary
AU - Heaton, Bethany J.
AU - Plant-Hately, Alexander
AU - David, Christopher
AU - Liptrott, Neill J.
AU - Egizabal, Ainhoa
AU - Ayerdi-Izquierdo, Ana
AU - Alvarez, Noelia
AU - Ibarrola, Oihane
AU - Celaya, Andres Arbona
AU - Del Pozo Perez, Angel
AU - Lazcanoiturburu, Nerea
AU - Luzuriagaf, Iris
AU - Zegeye, Fikirte Debebe
AU - Zienolddiny-Narui, Shanbeh
AU - Jacobs, An
AU - Van Driessche, Alexandra
AU - Nelissen, Inge
AU - Abasolo, Ibane
AU - Andrade, Fernanda
AU - Ventosa, Nora
AU - González-Mira, Elisabet
AU - Carreño, Aida
AU - Prina-Mello, Adriele
N1 - Publisher Copyright:
© 2024 The Royal Society of Chemistry.
PY - 2024/10/24
Y1 - 2024/10/24
N2 - Endotoxin contamination is a significant hurdle to the translation of nanomaterials for biomedical applications. Multiple reports now describe that more than one-third of nanomaterials fail early pre-clinical assessment due to levels of endotoxin above regulatory requirements. Additionally, most immunological studies or in vivo studies testing nanomaterials in the literature lack inclusion of this assessment, which may lead to false-positive or false-negative results if high levels of the contaminant are present. The currently approved methods for endotoxin contamination assessment rely on enzymatic activity and wavelength absorbance as their endpoint, and many nanomaterials can interfere with such assays. For this reason, we devised an interlaboratory comparison of endotoxin contamination assessment for a range of nanomaterials to challenge the current international organization for standardization and pharmacopeia standards. Herein, we show that detected endotoxin levels could vary considerably between groups, and, in some instances, nanomaterials could both pass and fail regulatory endotoxin limits for medical devices depending on the group undertaking the assessment, all while passing all quality criteria standards. This work emphasises the requirement for multiple assays to fully assess the endotoxin levels in a nanomaterial and highlights the need for additional assays to be developed in this space.
AB - Endotoxin contamination is a significant hurdle to the translation of nanomaterials for biomedical applications. Multiple reports now describe that more than one-third of nanomaterials fail early pre-clinical assessment due to levels of endotoxin above regulatory requirements. Additionally, most immunological studies or in vivo studies testing nanomaterials in the literature lack inclusion of this assessment, which may lead to false-positive or false-negative results if high levels of the contaminant are present. The currently approved methods for endotoxin contamination assessment rely on enzymatic activity and wavelength absorbance as their endpoint, and many nanomaterials can interfere with such assays. For this reason, we devised an interlaboratory comparison of endotoxin contamination assessment for a range of nanomaterials to challenge the current international organization for standardization and pharmacopeia standards. Herein, we show that detected endotoxin levels could vary considerably between groups, and, in some instances, nanomaterials could both pass and fail regulatory endotoxin limits for medical devices depending on the group undertaking the assessment, all while passing all quality criteria standards. This work emphasises the requirement for multiple assays to fully assess the endotoxin levels in a nanomaterial and highlights the need for additional assays to be developed in this space.
UR - http://www.scopus.com/inward/record.url?scp=85207311496&partnerID=8YFLogxK
U2 - 10.1039/d4nr02821j
DO - 10.1039/d4nr02821j
M3 - Article
AN - SCOPUS:85207311496
SN - 2040-3364
VL - 16
SP - 21011
EP - 21020
JO - Nanoscale
JF - Nanoscale
IS - 45
ER -